PMDD — Premenstrual Dysphoric Disorder
PMDD, Premenstrual Dysphoric Disorder. Neurobiology, differential diagnosis and personalized treatment with SSRIs and pharmacogenomics by psychiatrist Paschalis Gkikas.
PMDD — Premenstrual Dysphoric Disorder
PMDD is not “bad mood before the period”. It is a clinically recognized neurobiological condition that seriously affects quality of life, relationships and occupational functioning at regular intervals every month — and it can be treated effectively.
What is PMDD?
Premenstrual Dysphoric Disorder (PMDD) is a psychiatric condition included in DSM-5 (ICD-11 code: GA34.41). It is characterized by severe emotional, cognitive and physical symptoms during the luteal phase of the menstrual cycle — 1 to 2 weeks before menstruation — which remit rapidly with the onset of menstruation.
PMDD affects 3–8% of women of reproductive age. It differs fundamentally from Premenstrual Syndrome (PMS) in severity: PMDD symptoms are dysphoric to the point that they significantly impair functioning.
Clinical presentation and symptoms
For a PMDD diagnosis, at least 5 symptoms must be present during the luteal phase, with at least 1 of the 4 core symptoms.
Core symptoms — at least 1 of 4
- Marked mood swings, sudden changes, tearfulness
- Irritability, anger or increased interpersonal conflicts
- Depressed mood, sense of hopelessness or self-deprecating thoughts
- Anxiety, tension, feeling “on edge”
Additional symptoms
- Reduced interest in usual activities
- Difficulty concentrating
- Fatigue, lack of energy
- Appetite changes, food cravings
- Hypersomnia or insomnia
- Sense of being out of control
- Physical symptoms: breast tenderness, bloating, headaches, myalgia
Critical diagnostic requirement: Symptoms must be documented prospectively in a daily record for at least 2 consecutive cycles — retrospective reporting is not sufficient for a secure diagnosis.
Neurobiological basis
The key to understanding PMDD is not hormonal imbalance — progesterone and estrogen levels are usually normal. The problem is pathological brain sensitivity to normal hormonal fluctuations:
- Allopregnanolone and GABA: The main metabolite of progesterone normally enhances GABA-A receptors, producing calmness. In women with PMDD, the brain reacts paradoxically — allopregnanolone produces anxiety and dysphoria instead of calmness.
- Serotonergic dysfunction: The fall in estrogen during the luteal phase reduces serotonergic transmission. In women with PMDD, this reduction has a disproportionately strong clinical effect.
- Amygdala: Neuroimaging studies show amygdala hyperactivity in response to emotional stimuli during the luteal phase in women with PMDD.
- Genetics: Variants in ESC/E(Z) genes, epigenetic regulators, have been identified as a biological basis of increased sensitivity.
Treatment approach
PMDD responds extremely well to treatment when correctly diagnosed. Paschalis Gkikas applies a structured treatment plan that begins with full psychiatric assessment and calendar-based documentation of symptoms.
First-line treatments
- SSRIs based on PGx — continuous or luteal-phase dosing: SSRIs, particularly fluoxetine, sertraline and escitalopram, are the first pharmacological option. They may be given throughout the cycle or only during the luteal phase. Pharmacogenomic analysis selects the ideal SSRI and dosing strategy for each patient.
- Hormonal treatments: Combined contraceptives, especially those containing drospirenone, or GnRH agonists in selected cases — in collaboration with a gynecologist.
- CBT: Cognitive restructuring of dysfunctional thoughts and regulation of emotional response during exacerbation phases.
Second-line and special interventions
- Comorbidity assessment: Depression, anxiety disorders, PTSD and ADHD often become more severe during the luteal phase. PMDD may “unmask” an underlying psychiatric condition requiring separate treatment.
- Lifestyle management: Aerobic exercise, reduction of caffeine and alcohol, and sleep regulation — interventions with proven effects on serotonergic function.
- Supplements: Calcium (1200 mg/day), vitamin B6 and magnesium have supportive evidence — always in consultation with the psychiatrist.
Frequently asked questions (FAQ)
What is the difference between PMS and PMDD?
PMS includes mild-to-moderate physical and emotional symptoms that do not seriously affect functioning. PMDD involves intense dysphoric mood, anxiety or irritability that significantly disrupts work, relationships or social life — and meets specific diagnostic criteria.
Do I need to take medication all month?
Not necessarily. Luteal-phase dosing — SSRIs only for the 2 weeks before menstruation — is equally effective for many patients. The choice is individualized according to the clinical picture.
Can PMDD affect my relationships?
Yes. It is one of the most common consequences reported by patients. Intense irritability and emotional fluctuations can create serious interpersonal difficulties. Early treatment has a direct impact on relationship quality.
Does PMDD disappear with menopause?
Symptoms remit when menstrual cycles stop. However, the perimenopausal period — with intense hormonal fluctuations — can temporarily worsen symptoms before they stop definitively.
